BioLineRx Out-Licenses Novel Skin Lesion Treatment to Omega PharmaBusiness Wire (press release)Because the treatment is non-invasive, it poses minimal infection risk and eliminates the need for anesthesia or bandaging. The product has completed a phase 1/2 pilot clinical study for the removal of seborrheic keratosis, which showed excellent …Roth 'Encouraged' by Progress, Biz Development of BioLineRx's (BLRX) BL …StreetInsider.com (subscription)all 7 news articles »
[monetize id=”1″]
[monetize id=”2″]
Aclaris Therapeutics Announces Positive Results from Phase 2b Clinical Trial …Business Wire (press release)In the trial, A-101 demonstrated clinically and statistically significant improvements in clearing multiple seborrheic keratoses (SK), one of the most common types of skin tumors. Though the lesions are benign, many patients elect to have SK treated …and more »